AstraZeneca vaccine by Siam Bioscience passes quality tests; first batch delivery is near

AstraZeneca vaccine by Siam Bioscience passes quality tests; first batch delivery is near
-A +A

BANGKOK (May 9): The AstraZeneca Covid-19 vaccine made by Thai biopharmaceuticals manufacturer, Siam Bioscience Co Ltd, has passed numerous quality control tests and the delivery of the first batch is near.

AstraZeneca (Thailand) Ltd country president James Teague said the samples from test batches of the Covid-19 vaccine made by Siam Bioscience had passed the quality testing at AstraZeneca's global analytical laboratories in Europe and in the United States.

"These significant progresses mean that we are getting closer to deliver the first batch of the vaccine to the government of Thailand," he said in a statement.

Earlier, Thai Food and Drug Administration (FDA) approved Siam Bioscience as a manufacturing facility for AstraZeneca's Covid-19 vaccine.

Last week, the samples of AstraZeneca's Covid-19 vaccine made by Siam Bioscience passed the standard full tests set by Thailand's Department of Medical Sciences (DMS) for requirements such as chemical composition and safety.

AstraZeneca reiterated numerous safety tests and quality control measures have been carried out at each step of manufacturing and distribution including the quality assurance process, with each batch of vaccine undergoing more than 60 different quality control tests during its journey from manufacture to vaccination.

Meanwhile, Teague said AstraZeneca will work closely with local health authorities such as the Thai FDA and the DMS to fulfill local standards.

"Our focus is on delivering vaccines as quickly as possible whilst ensuring adherence to the highest safety and quality standards and processes.

"We will continue to work closely with the government to achieve that. We are well aware that increasing concerns and question on vaccine safety and the availability of supply to help Thais and the people in Southeast Asia to fight this terrible Covid-19 pandemic.

"I want to once again reiterate AstraZeneca's commitment that we are putting science and the interest of society at the heart of our work and we will remain true to our values by continuing to work with governments and other organisations towards broad and equitable access to the vaccine in a timely manner and Siam Bioscience is set to produce Covid-19 vaccine for eight Southeast Asia countries, (as well as) to produce its first batch of vaccine for the Thailand government in June of this year."

The mass vaccination in Thailand is set to start in June when the first batch of locally manufactured AstraZeneca vaccine is available.

AstraZeneca's Covid-19 vaccine has been granted a conditional marketing authorisation for emergency use in more than 70 countries, with the World Health Organization's Emergency Use Listing now accelerating the pathway to access in up to 142 countries through the COVAX facility.